BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed AXSM catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:fde43515a10285da20b6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:AXSM P3 readout (est.): ENGAGE
DESCRIPTION:Elucidating TAAR-1\, Dopamine\, and Norepinephrine in Binge Eat
 ing Disorder Using Solriamfetol\nNCT06413433 | PHASE3 | RECRUITING | spons
 or: Axsome Therapeutics\, Inc.\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nDate precision: month (shown on the fi
 rst day)\nTicker AXSM (confidence 0.9)\nSource: https://clinicaltrials.gov
 /study/NCT06413433\nScheduling/reference data from public records\; dates 
 can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06413433
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:07e8339bbd07be8fb9a2@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:AXSM P3 readout (est.): Studying Solriamfetol Modulation of TAAR-1\
 , Dopamine\, and Norepinephrine in Shift Work Disorder (SUSTAIN)
DESCRIPTION:Studying Solriamfetol Modulation of TAAR-1\, Dopamine\, and Nor
 epinephrine in Shift Work Disorder (SUSTAIN)\nNCT06568367 | PHASE3 | RECRU
 ITING | sponsor: Axsome Therapeutics\, Inc.\nPrimary completion date (ESTI
 MATED)\; top-line results usually follow later.\nDate precision: month (sh
 own on the first day)\nTicker AXSM (confidence 0.9)\nSource: https://clini
 caltrials.gov/study/NCT06568367\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06568367
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5b028eed19e20fbdee33@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:AXSM PDUFA (company-disclosed): PDUFA May 1\, 2027 - Axsome Therape
 utics\, Inc.
DESCRIPTION:PDUFA May 1\, 2027 - Axsome Therapeutics\, Inc.\nConfidence: co
 mpany-disclosed\nTicker AXSM (confidence 1.0)\nSource: https://www.sec.gov
 /Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm\nSchedulin
 g/reference data from public records\; dates can move. Not investment\, le
 gal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm
 -ex99_1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:417a93461e92fe84c968@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260430
DTEND;VALUE=DATE:20260501
SUMMARY:AXSM APPROVAL: AUVELITY
DESCRIPTION:Approved 2026-04-30: AUVELITY (NDA215430 SUPPL18)\nConfidence: 
 confirmed\nTicker AXSM (confidence 0.9)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215430\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215430
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
